Gongcheng Kexue Xueba

ISSN 2095-9389

Volume 11 || Issue 5 || 2026

Impact Factor: 6.7

https://kexuexuebao.org/

Editorial Board

GONGCHENG KEXUE XUEBAO

Table Of Contents

"A REVIEW ON DIGITAL PHARMACEUTICS: INTEGRATION OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DRUG DEVELOPMENT"

M. Babylatha[1*], Dr. C. Rajan[1], Dr.K. Geetha[1], Dr. D. Senthil rajan [1],

Professor[1*], Professor[1], Professor[1], Professor[1],

1. Department of Information Technology, Paavai Engineering College, Pachal, Namakkal, Tamil Nadu - 637018.
2. Department of CSE (Artificial Intelligence and Machine Learning), K. S. Rangasamy College of Technology, KSR Kalvi Nagar, Tiruchengode, Namakkal, Tamil Nadu - 637215.
3. Department of Computer Science and Engineering, Excel Engineering College, Pallakkapalayam, Komarapalayam, Tamil Nadu - 637303.
4. Department of Pharmaceutics, Swamy Vivekananda College of Pharmacy, Tiruchengodu, Namakkal - 637 205, India. (Affiliated to The Tamilnadu Dr. M.G.R. Medical University), Chennai.

CORRESPONDING AUTHOR:

M. BABYLATHA.

Assistant professor, Department of Information Technology, Paavai Engineering College, Pachal, Namakkal, Tamil Nadu 637018.

ABSTRACT:

Digital pharmaceutics is a revolutionary paradigm that has been made possible by the merging of digital technologies and pharmaceutical sciences. The integration of artificial intelligence (AI) and machine learning (ML), which are transforming the processes of drug discovery, development, and delivery, lies at the heart of this progress. The use of AI and ML in drug development, including target identification, lead optimization, pharmacokinetic modeling, personalized medicine, and clinical trial design, is examined in this overview along with new developments. By using data-driven methodologies, AI algorithms greatly improve forecast accuracy, shorten development times, and cut related expenses. The R&D process is being streamlined by the growing use of machine learning models for biomarker identification, medication repurposing, and virtual screening. Additionally, digital pharmaceutics is making it possible to create adaptive therapies that are customized to each patient's unique profile and intelligent drug delivery systems. Notwithstanding its potential, issues like algorithm transparency, regulatory frameworks, and data privacy still exist. With a focus on their revolutionary potential in the pharmaceutical sector, this paper offers a thorough summary of the technological developments, important applications, and prospects for the future of AI and ML in digital pharmaceutics.

KEYWORDS:

Digital pharmaceutics, Predictive modeling, Data driven discovery, pharmaceutical innovation, Machine learning, Regulatory challenges.

INTRODUCTION:

Machine learning and deep learning algorithms have been implemented in several drug discovery processes such as peptide synthesis, structure-based virtual screening, ligand-based virtual screening, toxicity prediction, drug monitoring and release, pharmacophore modeling, quantitative structure–activity relationship, drug repositioning, poly pharmacology, and physiochemical activity(1). This review highlights the impactful use of AI in diverse areas of the pharmaceutical sectors viz. drug discovery and development, drug repurposing, improving pharmaceutical productivity, clinical trials, etc. to name a few, thus reducing the human workload as well as achieving targets in a short period(2). Furthermore, living healthcare issues include misdiagnosis, overtreatment, decreased productivity, under-utilized clinical data handling, significant cost and spending. Precision medicine has the potential to improve the traditional symptom-driven practice of medicine by intelligently integrating multi-omics profiles with clinical, imaging, epidemiological and demographic details to allow a wide range of earlier interventions for advanced diagnostics and tailoring better and economical personalized treatment(3). Historically, machine-learning approaches, which are one of the most important components of machine intelligence, have been used to generate various QSAR models for VS over the past few decades. The resulting models are based on molecular structures and target activities, such as physicochemical properties, therapeutic activities, and PK properties which can vary in the different stages of drug discovery(4). The probabilistic framework, which describes how to represent and manipulate uncertainty about models and predictions, plays a central role in scientific data analysis, machine learning, robotics, cognitive science, and artificial intelligence. This article provides an introduction to this probabilistic framework, and reviews some state-of the art advances in the field, namely, probabilistic programming, Bayesian optimisation, data compression, and automatic model discovery(5).

KEY AREAS OF INTEGRATION:

Artificial Intelligence (AI) and Machine Learning (ML) are transforming the traditional drug development pipeline by enhancing prediction accuracy, reducing time, and lowering costs. These technologies analyze vast datasets to identify new drug targets, optimize compounds, predict toxicity, and even personalize therapies. The integration of artificial intelligence and machine learning across key domains of digital pharmaceutics is transforming drug development into a highly efficient, data-driven, and patient-centric process, enabling faster innovation and improved therapeutic success.

- ❖ AI analyzes genomic, proteomic, and bioinformatics data
- ❖ Disease-associated genes
- ❖ Protein targets
- ❖ ML models predict drug–target interactions



FIGURE NO.1: KEY AREAS OF INTEGRATION

1. DRUG DISCOVERY:

After introducing the basic principles, alongside some application notes, of the various machine learning algorithms, the current state-of-the art of AI-assisted pharmaceutical discovery is discussed, including applications in structure- and ligand-based virtual screening, de novo drug design, physicochemical and pharmacokinetic property prediction, drug repurposing, and related aspects. Finally, several challenges and limitations of the current methods are summarized, with a view to potential future directions for AI-assisted drug discovery and design[6]. These architectures include linear and nonlinear principle component analysis, k-means clustering methods, partial least square projection to latent structures, decision trees, multivariate linear regression, linear discriminant analysis, support vector machines (SVMs), logistic and kernel regression, multi-layer Perceptrons and related neural network approaches[7]. The rapid development of both computer hardware, software, and algorithms, drug screening and design have benefited much from various computational methods which greatly reduce the time and cost of drug development. In general, bioinformatics can help reveal the key genes from a massive amount of genomic data and thus provide possible target proteins for drug screening and design[9].



FIGURE NO.2: DRUG DISCOVERY

S.NO.	ADVANTAGE	DISADVANTAGE	APPLICATION
1.	High Accuracy & Prediction Power	Model Interpretability Issues	Bioinformatics & Target Identification
2.	Handling Big Data	Algorithm Limitations	Drug Repurposing
3.	Automation & Scalability	High Computational Cost	Machine Learning Algorithms Used

4.	Innovation in Drug Design	Validation Challenges	Property Prediction

TABLE NO.1: ADVANTAGES, DISADVANTAGE, APPLICATION OF DRUG DISCOVERY

2. PRECLINICAL DEVELOPMENT:



FIGURE NO.3: PRECLINICAL DEVELOPMENT

❖ **AI PREDICT OF ABSORBTION:**

Predicting human pharmacokinetics (PK) of candidate molecules in preclinical development has been an essential task for the successful planning of forth coming clinical development. The human exposure is calculated using four PK parameters of bioavailability (F), oral absorption rate constant (ka), the volume of distribution (Vd), and clearance (CL)[9]. Discovery of drugs has already been advanced with AI and ML, that have made substantial advances in a few scientific domains, including CADD. DL is excellent at predicting medication qualities, analysing chemical structures, and improving molecular design, particularly when combined with CNNs[10]. Success rates of drug development projects remain low despite major advances in enabling technologies, such as combinatorial chemistry, gene editing, multidimensional omics profiling, and phenotypic screening[11].

❖ **AI PREDICT OF DISTRIBUTION:**

The AI models were trained to predict eight types of key propertie (solubility, pKa values, crystal density, intrinsic dissolution rate, apparent permeability, protein unbound fraction, plasma clearance, and tissue partition coefficients for 15 organs), from which the PBPK model forecasted PK curves without further training(12). In recent years, several advances and promising developments in drug distribution property prediction have been achieved, especially in silico, which helped to drastically reduce the time and expense of screening undesired drug candidates. In this study, we provide comprehensive knowledge of drug distribution background, influencing factors, and artificial intelligence-based distribution property prediction models from 2019 to the present(13).

❖ AI PREDICT OF METABOLISM:

Metabolism can be the underlying cause of drug adverse effects and diminished efficacy. Metabolic reactions in the human body, mediated mainly by enzymes, may transform the administered drug into metabolites that exhibit different biological activity Molecular docking, quantitative structure to activity relationship (QSAR) studies modeling, molecular interaction fields, and quantum mechanical simulations have been used to model interactions between enzymes and molecules, and to predict regioselectivity(14). Drug metabolism and excretion play critical roles in the pharmacokinetics of drugs and have important implications for the R&D of new drugs, as well as for the safe and effective use of existing drugs. By understanding and predicting drug metabolism and excretion, researchers can screen unwanted drug candidates and design new drugs with improved pharmacokinetics, reduced toxicity, and increased efficacy(15).

❖ AI PREDICTOF EXCRETION:

This research delves into the application of AI-driven systems for predictive modeling in pharmacokinetics and pharmacodynamics, emphasizing the development and optimization of machine learning (ML) models to accurately predict the absorption, distribution, metabolism, and excretion (ADME) of drugs(16). Accelerated drug discovery pipelines, the rise of customized medicine powered by predictive models, optimized clinical trials, and a change in medication repurposing tactics are all envisaged in this. The report emphasizes the revolutionary potential of ML in altering pharmaceutical research and development while noting obstacles in data quality, model interpretability, ethics, and interdisciplinary collaboration(17). AI has been used in de novo drug design, activity scoring, virtual screening and in silico evaluation in the properties (absorption, distribution, metabolism, excretion and toxicity) of a drug molecule. Various pharmaceutical companies have teamed up with AI companies for faster progress in the field of drug development, along with the healthcare system. The review covers various aspects of AI (Machine learning, Deep learning, Artificial neural networks) in drug design(18).

❖ AI PREDICT OF TOXICITY:

This present review offers an in-depth examination of the role of AI and ML in the early detection of ADRs and toxicity, incorporating a wide range of methodologies ranging from data mining to deep learning followed by a list of important databases, modeling algorithms, and software that could be used in modeling and predicting a series of ADRs and toxicity(19). In this review, to aid the understanding of nano–bio interactions from environmental and health and safety perspectives, the potential, reality, challenges, and future advances that artificial intelligence (AI) and machine learning (ML) present are described. Herein, AI and ML algorithms that assist in the reporting of the minimum information required for biomaterial characterization and aid in the development and establishment of standard operating procedures are focused[20].

S.NO.	ADVANTAGE	DISADVANTAGE	APPLICATION
1.	Early Drug Candidate Screening	Data Quality Dependency	Toxicity Assessment
2.	Better Pharmacokinetic Profiling	Oversimplification of Biological Systems	Regulatory Support
3.	Integration with AI/ML	Prediction Accuracy Issues	Personalized Medicine

TABLE NO.2: ADVANTAGES, DISADVANTAGE, APPLICATION OF ADMET PRETICTION

3.PRECISION MEDICINE:

Developing multifunctional machine learning platforms for clinical data extraction, aggregation, management and analysis can support clinicians by efficiently stratifying subjects to understand specific scenarios and optimize decision-making[21]. The term “precision medicine” refers to the identification of a subpopulation within a large population, which is different from their disease risk, prognosis, detection, and response to treatment due to differences in their habitat, physiology, and other characteristics. The emphasis of personalized medicine is placed on tailored prevention, diagnosis, and treatment for each individual based on individual genetics, phenotype, epigenetics, and lifestyle[22]. Target identification is multidisciplinary field that involves biology, biochemistry, genetics, biophysics, and other related fields. The identified target could be a protein, gene, mRNA, or other molecules[23]. ML approaches have devised various algorithms to deduce and develop high throughput sequencing, phenotyping, and metabolomics approaches. These advancements are economical, more precise, and time-efficient. As a result, SNP (Single Nucleotide Polymorphisms) has emerged as a clinical genomic signature for novel drug discovery and target prediction inhealthomics[24].



FIGURE NO.4: PRECISION MEDICINE

S.NO.	ADVANTAGE	DISADVANTAGE	APPLICATION
1.	Improved Clinical Outcomes	Data Privacy & Security Issues	Healthomics & Biomarker Discovery
2.	Integration of Multidisciplinary Data	Complexity of Biological Systems	Omics-Based Drug Discovery
3.	Integration of Multidisciplinary Data	Data Quality Dependency	Target Identification in Drug Discovery

TABLE NO.3: ADVANTAGES, DISADVANTAGE, APPLICATION OF PRECISION MEDICINE

4. DRUG REPURPOSING:

Exciting opportunities to apply ML and AI methods occur in all stages of drug discovery and development, including target identification and validation, prediction of molecular structure and function, and compound screening and optimization. Based on high-quality training data, supervised learning and feature selection offers a systematic means for identification of predictive biomarkers for precision medicine(25). The study leverages the superior natural language processing capabilities of transformer architectures, specifically BERT and GPT variants, to efficiently analyze extensive pharmaceutical data, including chemical structures, genomic sequences, and biomedical literature. By employing transfer learning techniques, these models are adept at identifying potential drug candidates and predicting their interactions with biological targets(26). Computationally identifying new targets for existing drugs has drawn much attention in drug repurposing due to its advantages over de novo drugs, including low risk, low costs, and rapid pace. To facilitate the drug repurposing computation, we constructed an automated and parameter-free virtual screening server, namely DrugRep, which performed molecular 3D structure construction, binding pocket prediction, docking, similarity comparison and binding affinity screening in a fully automatic manner(27).



FIGURE NO.5: DRUG REPURPOSING

S. NO.	LIMITATIONS OF AI-BASED DRUG REPURPOSING	FUTURE DIRECTIONS
1.	Lack of Mechanistic Interpretabil	Advanced Deep Learning & Hybrid Models
2.	Computational and Infrastructure Constraints	Real-World Evidence (RWE) Expansion
3.	Experimental and Clinical Validation Gap	Integration with Digital Health Technologies

TABLE NO.4: ADVANTAGES, DISADVANTAGE, APPLICATION OF DRUG REPURPOSING

5. CLINICAL TRIALS:

Digital pharmaceutics has emerged as a transformative paradigm in modern clinical research, characterized by the seamless integration of artificial intelligence (AI), machine learning (ML), big data analytics, and digital health ecosystems into the drug development lifecycle. This evolution is driven by the need to overcome the inherent limitations of conventional clinical trials, which are often time-consuming, costly, inflexible, and dependent on centralized infrastructures. In contrast, digital pharmaceutics redefines clinical trials as adaptive, data-driven, and patient-centric frameworks, capable of continuous learning and real-time optimization[28]. At the core of this transformation lies the ability of AI and ML algorithms to process, integrate, and interpret large-scale heterogeneous datasets, including electronic health records (EHRs), genomic and multi-omics data, wearable sensor outputs, and real-world evidence (RWE). These technologies facilitate predictive modeling, pattern recognition, and clinical decision support, enabling researchers to design smarter trials with optimized endpoints, improved patient selection, and enhanced safety monitoring[29]. A critical advancement within digital pharmaceutics is the emergence of decentralized and hybrid clinical trial models, supported by mobile health technologies, telemedicine platforms, and remote monitoring tools. These innovations enhance patient accessibility, compliance, and diversity, while simultaneously generating continuous, high-resolution datasets that improve the reliability of clinical outcomes[30].

S.NO.	ADVANCED AI TECHNOLOGIES IN CLINICAL TRIALS	FUTURE DIRECTIONS
1.	Natural Language Processing (NLP)	digital twins in precision medicine
2.	Reinforcement Learning	pharmacovigilance using AI
3.	Digital Twins	explainable AI (XAI)

TABLE NO.5: ADVANTAGES, DISADVANTAGE, APPLICATION OF CLINICAL TRIALS

CONCLUSION:

Machine intelligence has been applied in the drug discovery field for decades. Traditional machine-learning modeling has evolved into a variety of new methods. AI/ML Technologies significantly reduce the time, cost, and failure rates associated with trational drug discovery and development processes, From target identification of drug discovery, Preclinical development, Precision medicine, Drug repurposing, and decision making across every stage of the drug lifecycle. AI/ML and pharmaceutics not only redefines drug development strategies but also paves the way for more individualized, effective, and accessible therapeutic solutions. Continued innovation and responsible integration of these technologies will be crucial in shaping the future of pharmaceutical science.

ACKNOWLEDGEMENT:

I here by thank to Department of Pharmaceutics, Swamy vivekanandha college of Pharmacy, Tiruchengode, Namakkal(Dt).

CONFLICT OF INTEREST:

We declare that we have no conflict of interest.

REFERENCE:

1. Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Molecular diversity. 2021 Aug;25:1315-60.
2. Mak KK, Wong YH, Pichika MR. Artificial intelligence in drug discovery and development. Drug discovery and evaluation: safety and pharmacokinetic assays. 2024 Oct 22:1461-98.
3. Ahmed Z, Mohamed K, Zeeshan S, Dong X. Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. Database. 2020;2020:baaa010.

4. Zhang L, Tan J, Han D, Zhu H. From machine learning to deep learning: progress in machine intelligence for rational drug discovery. Drug discovery today. 2017 Nov 1;22(11):1680-5.
5. Ghahramani Z. Probabilistic machine learning and artificial intelligence. Nature. 2015 May 28;521(7553):452-9.
6. Yang X, Wang Y, Byrne R, Schneider G, Yang S. Concepts of artificial intelligence for computer-assisted drug discovery. Chemical reviews. 2019 Jul 11;119(18):10520-94.
7. Gawehn E, Hiss JA, Schneider G. Deep learning in drug discovery. Molecular informatics. 2016 Jan;35(1):3-14.
8. Lin X, Li X, Lin X. A review on applications of computational methods in drug screening and design. Molecules. 2020 Mar 18;25(6):1375.
9. Yim DS, Choi S, Bae SH. Predicting human pharmacokinetics from preclinical data: absorption. Translational and Clinical Pharmacology. 2020 Sep 21;28(3):126.
10. Khan SW, Pandey A, Mishra S, Budha RR. Advances in the Computational Prediction of Absorption Prediction of Pharmaceuticals. InApplications of Computational Tools in Drug Design and Development 2025 (pp. 387-425). Springer, Singapore.
11. Kemas AM, Zandi Shafagh R, Taebnia N, Michel M, Preiss L, Hofmann U, Lauschke VM. Compound absorption in polymer devices impairs the translatability of preclinical safety assessments. Advanced Healthcare Materials. 2024 Apr;13(11):2303561.
12. Wang W, Wang N, Wu Y, Ye Z, Zhao L, Chen X, Ouyang D. An Integrated AI-PBPK Platform for Predicting Drug In Vivo Fate and Tissue Distribution in Human and Inter-Species Extrapolation. Clinical Pharmacology & Therapeutics. 2025 May 28.
13. Tran TT, Tayara H, Chong KT. Recent studies of artificial intelligence on in silico drug distribution prediction. International Journal of Molecular Sciences. 2023 Jan 17;24(3):1815.
14. Litsa EE, Das P, Kavraki LE. Machine learning models in the prediction of drug metabolism: Challenges and future perspectives. Expert opinion on drug metabolism & toxicology. 2021 Nov 2;17(11):1245-7.
15. Tran TT, Tayara H, Chong KT. Artificial intelligence in drug metabolism and excretion prediction: recent advances, challenges, and future perspectives. Pharmaceutics. 2023 Apr 17;15(4):1260.
16. Mitta NR. AI-Driven Systems for Predictive Pharmacokinetics and Pharmacodynamics Modeling: Developing Machine Learning Models for Accurate Drug Absorption, Distribution, Metabolism, and Excretion Predictions. Newark Journal of Human-Centric AI and Robotics Interaction. 2023 Nov 2;3:389-421.
17. Husnain A, Rasool S, Saeed A, Hussain HK. Revolutionizing pharmaceutical research: Harnessing machine learning for a paradigm shift in drug discovery. International Journal of Multidisciplinary Sciences and Arts. 2023 Sep 27;2(4):149-57.
18. Sahu A, Mishra J, Kushwaha N. Artificial intelligence (AI) in drugs and pharmaceuticals. Combinatorial chemistry & high throughput screening. 2022 Sep 1;25(11):1818-37.
19. Yang S, Kar S. Application of artificial intelligence and machine learning in early detection of adverse drug reactions (ADRs) and drug-induced toxicity. Artificial Intelligence Chemistry. 2023 Dec 1;1(2):100011.
20. Singh AV, Rosenkranz D, Ansari MH, Singh R, Kanase A, Singh SP, Johnston B, Tentschert J, Laux P, Luch A. Artificial intelligence and machine learning empower advanced biomedical material design to toxicity prediction. Advanced Intelligent Systems. 2020 Dec;2(12):2000084.
21. Ahmed Z, Mohamed K, Zeeshan S, Dong X. Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. Database. 2020;2020:baaa010.
22. Sahu M, Gupta R, Ambasta RK, Kumar P. Artificial intelligence and machine learning in precision medicine: A paradigm shift in big data analysis. Progress in molecular biology and translational science. 2022 Jan 1;190(1):57-100.
23. Hasanzad M, Nosrati M, Khatami F, Rahmani P, Sarhangi N, Nikfar S, Abdollahi M. Drug discovery in the context of precision medicine and artificial intelligence. Expert Review of Precision Medicine and Drug Development. 2024 Dec 31;9(1):42-53.

24. Joshi I, Bhrdwaj A, Khandelwal R, Pande A, Agarwal A, Srija CD, Suresh RA, Mohan M, Hazarika L, Thakur G, Hussain T. Artificial intelligence, big data and machine learning approaches in genome-wide SNP-based prediction for precision medicine and drug discovery. InBig data analytics in chemoinformatics and bioinformatics 2023 Jan 1 (pp. 333-357). Elsevier.

25. Aittokallio T. What are the current challenges for machine learning in drug discovery and repurposing?. Expert opinion on drug discovery. 2022 May 4;17(5):423-5.

26. Kalusivalingam AK, Sharma A, Patel N, Singh V. Enhancing Drug Discovery and Repurposing through Transformer Models and Reinforcement Learning Algorithms. International Journal of AI and ML. 2021 Feb 15;2(3).

27. Gan JH, Liu JX, Liu Y, Chen SW, Dai WT, Xiao ZX, Cao Y. DrugRep: an automatic virtual screening server for drug repurposing. Acta Pharmacologica Sinica. 2023 Apr;44(4):888-96.

28. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nature medicine. 2019 Jan;25(1):44-56.

29. Harrer S, Shah P, Antony B, Hu J. Artificial intelligence for clinical trial design. Trends in pharmacological sciences. 2019 Aug 1;40(8):577-91.

30. Izmailova ES, Wagner JA, Perakslis ED. Wearable devices in clinical trials: hype and hypothesis. Clinical Pharmacology & Therapeutics. 2018 Jul;104(1):42-52.